Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorPileri, S.A. (S.A.)
dc.creatorZinzani, P.L. (P.L.)
dc.creatorWent, P. (P.)
dc.creatorPileri, Jr., A. (A.)
dc.creatorBendandi, M. (Maurizio)
dc.identifier.citationPileri SA, Zinzani PL, Went P, Pileri A,Jr, Bendandi M. Indolent lymphoma: the pathologist's viewpoint. Ann Oncol 2004 Jan;15(1):12-18.es_ES
dc.description.abstractAbstract Indolent lymphomas have recently been the object of numerous studies, which have focused on new aspects relevant both for the better comprehension of their histogenesis and the identification of new therapeutic strategies. As marginal-zone lymphoma (MZL) represents the category of indolent lymphomas that has obtained more benefit from such an approach, the authors focused on the most recent achievements and not yet solved controversies in this area. In spite of their postulated common derivation, the three categories of MZL of the WHO Classification appear dissimilar. In fact, they show significant molecular differences among them as well as a certain heterogeneity within each group. By no means, there is a cogent need of more refined tools to revise these neoplasms and to produce a more rational grouping. The recent identification of the IRTA gene family corresponding to IG-like receptors differentially expressed in B-cells might contribute to their better understanding.es_ES
dc.publisherOxford University Presses_ES
dc.subjectExtranodal marginal zone lymphomaes_ES
dc.subjectIndolent Lymphomaes_ES
dc.subjectLymphoma Classificationes_ES
dc.subjectNodal marginal zone lymphomaes_ES
dc.subjectPrimary splenic marginal zone lymphomaes_ES
dc.titleIndolent lymphoma: the pathologist's viewpointes_ES

Ficheros en este ítem:
Vista previa
Ann Oncol_Indolent 2004_15pdf.pdf
110.06 kB
Adobe PDF

Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.